Trial Profile
Myeloma XII (ACCoRd): A phase III study to determine the role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 12 Jan 2024
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Ixazomib (Primary) ; Thalidomide (Primary) ; Melphalan
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms ACCoRd; Myeloma XII
- Sponsors Takeda
- 12 Dec 2023 Interim results of efficacy and safety presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 23 Nov 2023 Recruitment completion is expected on 31/05/2022 according to ISRCTN: Current Controlled Trials record.
- 23 Nov 2023 Planned End Date changed from 1 Mar 2027 to 30 Apr 2027.